Skip to search formSkip to main contentSkip to account menu

AFN 1252

Known as: AFN-1252, AFN1252 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
ABSTRACT This open-label noncontrolled, phase II multicenter trial was designed to evaluate the safety, tolerability, and… 
2015
2015
AIMS AFN-1252 is a novel inhibitor of FabI, an essential enzyme in Staphylococcus spp. This study was undertaken to assess the… 
2013
2013
Background: AFN-1252 is a FabI inhibitor developed to treat Staphylococcus aureus. Results: AFN-1252 resistance arises from a… 
2013
2013
Abstract AFN-1252 is a novel inhibitor of FabI, an essential enzyme in fatty acid biosynthesis in Staphylococcus spp. AFN-1252… 
2013
2013
Abstract AFN-1252, a new antimicrobial agent, specifically and potently inhibits fatty acid synthesis in Staphylococcus aureus… 
2013
2013
ABSTRACT This study examines the alteration in Staphylococcus aureus gene expression following treatment with the type 2 fatty… 
Highly Cited
2012
Highly Cited
2012
ABSTRACT The mechanism of action of AFN-1252, a selective inhibitor of Staphylococcus aureus enoyl-acyl carrier protein reductase… 
Highly Cited
2009
Highly Cited
2009
ABSTRACT AFN-1252, a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates of… 
1999
1999
Fibronectin (Fn) is a major adhesive protein found in the hepatic extracellular matrix (ECM). In adult rats, the in vivo turnover…